Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PREP | P48147 | 3/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12490662 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL8790790 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL2195118 | 0.96 | PREP (0.56) | SMN1; SMN2NPC1RAB9APREPACE2 | |
| SCHEMBL2198909 | 0.96 | PREP (0.56) | SMN1; SMN2NPC1RAB9APREPACE2 | |
| SCHEMBL2198876 | 0.96 | PREP (0.56) | SMN1; SMN2NPC1RAB9APREPACE2 | |
| SCHEMBL31603524 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL8639445 | 0.89 | PREP (0.65) | PREPCTRB1 | |
| SCHEMBL7118362 | 0.87 | PREP (0.48) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL7049870 | 0.87 | PREP (0.48) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL8790173 | 0.87 | PREP (0.48) | SMN1; SMN2NPC1RAB9APREPFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-216525615-U | Gas chromatograph for producing 4-1 formyl-N-CBZ piperidine | 武汉市振邦生物科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-216484471-U | Moisture meter for processing 4-1 formyl-N-CBZ piperidine | 武汉市振邦生物科技有限公司 | 2022-05-10 | — | — | CN | claimed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| CN-216525615-U | Gas chromatograph for producing 4-1 formyl-N-CBZ piperidine | 武汉市振邦生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-216525615-U | Gas chromatograph for producing 4-1 formyl-N-CBZ piperidine | 武汉市振邦生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-216525615-U | Gas chromatograph for producing 4-1 formyl-N-CBZ piperidine | 武汉市振邦生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-216484471-U | Moisture meter for processing 4-1 formyl-N-CBZ piperidine | 武汉市振邦生物科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-216484471-U | Moisture meter for processing 4-1 formyl-N-CBZ piperidine | 武汉市振邦生物科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-216484471-U | Moisture meter for processing 4-1 formyl-N-CBZ piperidine | 武汉市振邦生物科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-216296372-U | Constant-temperature water bath device for research and development of 4-formyl-N-CBZ piperidine | 武汉市振邦生物科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-0592438-B1 | INDOLE DERIVATIVES | PFIZER (US) | 1997-08-27 | — | — | EP | disclosed |
| US-5607951-A | SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS | PFIZER INC (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0747353-A2 | Indole derivatives | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0592438-A1 | INDOLE DERIVATIVES. | PFIZER (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | SMN1; SMN2 3461/4885NPC1 1758/4885RAB9A 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.